BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) has earned an average recommendation of “Moderate Buy” from the six analysts that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $42.60.

Several equities analysts have recently commented on BTAI shares. HC Wainwright lowered their price objective on shares of BioXcel Therapeutics from $80.00 to $48.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. RODMAN&RENSHAW upgraded BioXcel Therapeutics to a “strong-buy” rating in a research report on Wednesday. Canaccord Genuity Group decreased their target price on BioXcel Therapeutics from $112.00 to $80.00 and set a “buy” rating for the company in a report on Monday, January 6th. Bank of America reiterated an “underperform” rating and issued a $4.00 price target (down previously from $112.00) on shares of BioXcel Therapeutics in a report on Tuesday, January 7th. Finally, Rodman & Renshaw initiated coverage on shares of BioXcel Therapeutics in a report on Wednesday. They issued a “buy” rating and a $65.00 price objective for the company.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Squarepoint Ops LLC increased its stake in BioXcel Therapeutics by 203.9% during the 4th quarter. Squarepoint Ops LLC now owns 72,046 shares of the company’s stock valued at $27,000 after purchasing an additional 48,336 shares in the last quarter. Northern Trust Corp increased its holdings in BioXcel Therapeutics by 81.4% in the 4th quarter. Northern Trust Corp now owns 73,910 shares of the company’s stock worth $28,000 after buying an additional 33,161 shares in the last quarter. Wells Fargo & Company MN lifted its stake in BioXcel Therapeutics by 7.5% during the 4th quarter. Wells Fargo & Company MN now owns 199,010 shares of the company’s stock valued at $74,000 after acquiring an additional 13,952 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of BioXcel Therapeutics by 4.7% during the 4th quarter. Geode Capital Management LLC now owns 311,965 shares of the company’s stock valued at $117,000 after acquiring an additional 13,922 shares during the last quarter. 30.68% of the stock is currently owned by institutional investors.

BioXcel Therapeutics Stock Performance

NASDAQ:BTAI opened at $2.36 on Friday. BioXcel Therapeutics has a fifty-two week low of $1.72 and a fifty-two week high of $49.58. The business has a 50 day moving average price of $3.61 and a 200-day moving average price of $6.77. The firm has a market cap of $7.57 million, a PE ratio of -0.07 and a beta of 0.89.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.